We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+6.98%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.62B
AUM Growth
+$55.7M
Cap. Flow
+$25.7M
Cap. Flow %
1.58%
Top 10 Hldgs %
70.33%
Holding
44
New
7
Increased
12
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$45.1M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$31.4M
4
CTMX icon
CytomX Therapeutics
CTMX
+$30.7M
5
LEGN icon
Legend Biotech
LEGN
+$30.1M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$78.6M
2
TYRA icon
Tyra Biosciences
TYRA
+$41.1M
3
CGON icon
CG Oncology
CGON
+$39.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$28.6M
5
DVAX
Dynavax Technologies
DVAX
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
1
Syndax Pharmaceuticals
SNDX
$1.84B
$188M 11.6%
8,050,959
– –
CLDX icon
2
Celldex Therapeutics
CLDX
$2.77B
$185M 11.43%
5,840,567
-102,613
-2% -$2.8M
PCVX icon
3
Vaxcyte
PCVX
$7.89B
$170M 10.48%
2,922,335
– –
COGT icon
4
Cogent Biosciences
COGT
$6.79B
$155M 9.59%
4,037,331
-2,127,892
-35% -$78.6M
VERA icon
5
Vera Therapeutics
VERA
$2.54B
$137M 8.43%
3,398,224
-34,827
-1% -$1.5M
BEAM icon
6
Beam Therapeutics
BEAM
$2.58B
$87.7M 5.41%
3,682,185
+1,241,971
+51% +$34.5M
CTMX icon
7
CytomX Therapeutics
CTMX
$705M
$70.6M 4.35%
15,013,093
+6,047,016
+67% +$30.7M
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.37B
$54.1M 3.34%
5,680,795
-3,685,731
-39% -$28.6M
TVTX icon
9
Travere Therapeutics
TVTX
$5.33B
$46.6M 2.88%
1,569,018
+1,051,134
+203% +$31.4M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$45.8M 2.83%
2,341,652
+871,111
+59% +$25.9M
CGEM icon
11
Cullinan Oncology
CGEM
$1.05B
$44.3M 2.73%
3,114,132
– –
URGN icon
12
UroGen Pharma
URGN
$2B
$40.4M 2.49%
+2,247,393
New +$45.1M
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$36.7M 2.26%
1,820,954
+10,000
+0.6% +$161K
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
$33.2M 2.05%
825,000
-83,607
-9% -$1.8M
LEGN icon
15
Legend Biotech
LEGN
$4.3B
$28.5M 1.76%
+1,576,295
New +$30.1M
MBX
16
MBX Biosciences
MBX
$2.95B
$27.9M 1.72%
934,799
– –
IMCR icon
17
Immunocore
IMCR
$1.78B
$26.7M 1.65%
884,937
+28,475
+3% +$921K
TVTX icon
18
CALL
Travere Therapeutics
TVTX
$5.33B
$23.8M 1.47%
+800,000
New +$23.9M
STRO icon
19
Sutro Biopharma
STRO
$379M
$21.7M 1.34%
872,558
+392,968
+82% +$7.1M
RVMD icon
20
PUT
Revolution Medicines
RVMD
$40.2B
$20.2M 1.24%
+207,500
New +$21M
BNR
21
Burning Rock Biotech
BNR
$94.4M
$19.8M 1.22%
1,227,555
+232,672
+23% +$6.09M
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
$18.7M 1.16%
+560,000
New +$22M
NRIX icon
23
Nurix Therapeutics
NRIX
$2.43B
$18.5M 1.14%
1,194,757
-775,600
-39% -$12.9M
PHVS icon
24
Pharvaris
PHVS
$2.39B
$18.1M 1.12%
640,395
– –
EVMN
25
Evommune Inc
EVMN
$409M
$14.4M 0.89%
625,496
+440,014
+237% +$9.95M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Kynam Capital Management held 44 positions worth $1.62B, up 3.6% from $1.57B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Kynam Capital Management's Q1 2026 filing shows 7 new, 12 increased, 9 reduced and 5 closed positions. Its largest new stake was UroGen Pharma: 2,247,393 shares worth $40.4M. The largest sale was Cogent Biosciences, an estimated $78.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.

  • Kynam Capital Management's largest Q1 2026 buy was UroGen Pharma: 2,247,393 shares worth $40.4M.
  • Kynam Capital Management added most to Beam Therapeutics in Q1 2026, an estimated $34.5M increase.
  • Kynam Capital Management's biggest Q1 2026 reduction was Cogent Biosciences, cutting an estimated $78.6M.
  • Kynam Capital Management fully exited Tyra Biosciences in Q1 2026, selling an estimated $41.1M.
  • Kynam Capital Management's ten largest holdings make up 70% of its $1.62B portfolio in Q1 2026.
  • Kynam Capital Management opened 7 new positions and closed 5 in Q1 2026.
  • Kynam Capital Management's portfolio value rose 3.6% quarter-over-quarter to $1.62B.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.